Sat | Sep 23, 2017

Experimental Ebola vaccine showing promise

Published:Friday | July 31, 2015 | 7:27 AM
In this March 7, 2015 file photo, a health worker (right) cleans a man's arm before injecting him with a Ebola vaccine in Conakry, Guinea.

LONDON (AP):

An experimental Ebola vaccine tested on thousands of people in Guinea seems to work and might help shut down the waning epidemic in West Africa, according to interim results from a study published today.

There is currently no licensed treatment or vaccine for Ebola, which has so far killed more than 11,000 people in West Africa since the world's biggest outbreak began in the forest region of Guinea last year. Cases have dropped dramatically in recent months in the other two hard-hit countries, Sierra Leone and Liberia.

"If proven effective, this is going to be a game-changer," said Dr Margaret Chan, Director-General of the World Health Organization (WHO), which sponsored the study. "It will change the management of the current outbreak and future outbreaks."

 In this Tuesday, June 30, 2015, file photo, health workers take a blood specimen from a child to test for the Ebola virus in a area were a 17-year old boy died from the virus on the outskirts of Monrovia, Liberia.

In this Tuesday, June 30, 2015, file photo, health workers take a blood specimen from a child to test for the Ebola virus in a area were a 17-year old boy died from the virus on the outskirts of Monrovia, Liberia. - AP photo

Scientists have struggled for years to develop Ebola treatments and vaccines but have faced numerous hurdles, including the sporadic nature of outbreaks and funding shortages. Many past attempts have failed, including a recently abandoned drug being tested in West Africa by Tekmira Pharmaceuticals.

For the study, researchers gave one dose of the new vaccine to more than 4,000 health care workers and other people within 10 days of their close contact with a sick Ebola patient. Another group of 3,500 people got the shot more than 10 days after their exposure to the infectious virus. In the group that received the vaccine immediately, there were no Ebola cases versus 16 cases in people who got delayed vaccination.

The vaccine, developed by the Canadian government, has since been licensed to Merck & Co. but has not yet been approved by regulators. The study results were published online Friday in the journal Lancet.

At the moment, officials think the vaccine would only be used once an outbreak starts, to protect those at high-risk; there are no plans to introduce mass vaccination campaigns like those for measles or polio or to create huge stockpiles of the shots.

Merck, based in Kenilworth, New Jersey, noted its vaccine is in what is normally the final round of human testing in Sierra Leone, and in mid-stage testing in Liberia.

Merck will manufacture the vaccine if it's approved for use outside patient studies. In late-morning trading in the US, Merck shares were up 62 cents, or 1.1 per cent, at $59.13.

Last December, Gavi, the vaccine alliance, said it would spend up to $300 million buying approved Ebola vaccines. The private-public partnership, which often buys immunizations for poor countries, said Friday that it "stands ready to support the implementation of a WHO-recommended Ebola vaccine."

An expert group monitoring the study's data and safety recommended the trial be stopped on July 26 so that everyone exposed to Ebola in Guinea could be immunized.

In this Tuesday, June 30, 2015, file photo health workers wash their hands after taking a blood specimen from a child.

In this Tuesday, June 30, 2015, file photo health workers wash their hands after taking a blood specimen from a child. - AP photo

The vaccine uses an Ebola protein to prompt the body's immune system to attack the virus.

"It looks to be about as safe as a flu vaccine," said Ben Neuman, a virologist at the University of Reading who was not part of the trial. Researchers are still assessing possible side effects; the most serious seemed to be fever and the stress experienced by patients who believe such symptoms were due to Ebola.

"This (vaccine) could be the key that we've been missing to end the outbreak," Neuman said. "I don't see any reason on humanitarian grounds why it should not be used immediately." He said further tests would be necessary to see if the vaccine might also protect pregnant women, children and adolescents; those trials are already under way. It's also uncertain how long protection might last.

WHO vaccines expert Marie-Paule Kieny said having an effective vaccine might avert future disasters but added it would still take months to get the shot approved by regulators.

"Using a tool like this vaccine, we would be able to stop the epidemic from going really wild and spreading further," she told reporters, noting that stamping out future outbreaks still depends on early detection. WHO first identified Ebola in Guinea last March but did not declare the epidemic to be a global emergency until August, when the virus had killed nearly 1,000 people.

Other Ebola vaccines are being studied elsewhere but the declining caseload is complicating efforts to finish the trials.